Marksans Pharma Ltd
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]
- Market Cap ₹ 2,900 Cr.
- Current Price ₹ 64.0
- High / Low ₹ 69.6 / 38.6
- Stock P/E 14.7
- Book Value ₹ 31.1
- Dividend Yield 0.39 %
- ROCE 23.9 %
- ROE 18.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 83.7% CAGR over last 5 years
Cons
- Promoter holding has decreased over last quarter: -4.80%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
305 | 356 | 438 | 630 | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,667 | |
378 | 455 | 369 | 512 | 612 | 757 | 722 | 834 | 868 | 942 | 1,037 | 1,232 | 1,392 | |
Operating Profit | -73 | -100 | 69 | 118 | 185 | 136 | 45 | 78 | 132 | 192 | 340 | 259 | 275 |
OPM % | -24% | -28% | 16% | 19% | 23% | 15% | 6% | 9% | 13% | 17% | 25% | 17% | 16% |
-78 | 2 | 4 | 4 | 3 | 9 | 7 | 8 | 5 | 0 | 7 | 42 | 58 | |
Interest | 44 | 54 | 15 | 19 | 16 | 10 | 7 | 10 | 10 | 9 | 8 | 8 | 10 |
Depreciation | 20 | 24 | 16 | 16 | 16 | 28 | 30 | 27 | 23 | 27 | 36 | 45 | 55 |
Profit before tax | -215 | -175 | 44 | 86 | 156 | 107 | 15 | 50 | 104 | 157 | 302 | 248 | 267 |
Tax % | -3% | -1% | -12% | 15% | 28% | 23% | 24% | 28% | 23% | 23% | 21% | 25% | |
Net Profit | -222 | -176 | 49 | 74 | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 198 |
EPS in Rs | 1.19 | 1.87 | 2.67 | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 4.87 | ||
Dividend Payout % | 0% | -0% | 10% | 5% | 4% | 21% | 23% | 6% | 3% | 3% | 4% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 14% |
3 Years: | 14% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | 84% |
3 Years: | 34% |
TTM: | -20% |
Stock Price CAGR | |
---|---|
10 Years: | 34% |
5 Years: | 10% |
3 Years: | 52% |
1 Year: | 8% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 23% |
Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50 | 50 | 52 | 52 | 53 | 53 | 41 | 41 | 41 | 41 | 41 | 41 | 40 | |
Reserves | -115 | -220 | 34 | 90 | 326 | 401 | 392 | 430 | 502 | 595 | 846 | 1,068 | 1,223 |
135 | 179 | 163 | 160 | 89 | 88 | 110 | 118 | 100 | 30 | 34 | 111 | 100 | |
436 | 389 | 165 | 202 | 220 | 192 | 209 | 142 | 160 | 236 | 307 | 416 | 305 | |
Total Liabilities | 492 | 385 | 401 | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 1,668 |
279 | 165 | 156 | 146 | 166 | 270 | 267 | 279 | 270 | 303 | 309 | 428 | 438 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
213 | 220 | 245 | 344 | 510 | 452 | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,229 | |
Total Assets | 492 | 385 | 401 | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 1,668 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-65 | -62 | 39 | 65 | 155 | 31 | 14 | 50 | 27 | 233 | 179 | 99 | |
25 | -3 | -5 | -4 | -33 | -123 | -21 | -39 | -13 | -60 | -45 | -42 | |
36 | 57 | -40 | -29 | 17 | -58 | -3 | 3 | -21 | -114 | -15 | 80 | |
Net Cash Flow | -5 | -9 | -7 | 31 | 138 | -150 | -10 | 15 | -7 | 60 | 118 | 137 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 118 | 116 | 109 | 98 | 84 | 89 | 118 | 71 | 64 | 78 | 72 | 97 |
Inventory Days | 210 | 126 | 112 | 102 | 107 | 120 | 151 | 152 | 215 | 155 | 248 | 216 |
Days Payable | 172 | 100 | 81 | 83 | 88 | 85 | 129 | 54 | 78 | 71 | 103 | 102 |
Cash Conversion Cycle | 156 | 141 | 141 | 118 | 103 | 124 | 140 | 169 | 202 | 163 | 217 | 211 |
Working Capital Days | -270 | -218 | 37 | 48 | 55 | 95 | 130 | 117 | 133 | 94 | 110 | 138 |
ROCE % | -28% | -306% | 45% | 38% | 45% | 23% | 4% | 11% | 19% | 25% | 39% | 24% |
Documents
Announcements
- Submission Of Certificate From Statutory Auditor As per Regulation 169(5) Of The SEBI (Issue Of Capital And Disclosure Requirements) Regulations, 2018 24 Jan
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Jan
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Jan
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 23 Jan
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
23 Jan - Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Aug 2019TranscriptPPT
-
Aug 2019TranscriptPPT
Revenue Mix [1]
Around 30% comes from Pain Management, 18% comes from Anti-Diabetic, 15% comes from Cardiovascular System(CVS), 13% comes from Cough & Cold, and the rest comes from Gastrointestinal, Central Nervous System(CNS), etc.